Table: Anges - 9-MTH group results
Nov 5 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2021 Sep 30, 2020 Dec 31, 2021
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 44 mln 28 mln
(+56.9 pct) (-91.2 pct)
Operating loss 12.16 loss 2.86
Recurring loss 11.82 loss 3.15
Net loss 11.95 loss 3.17
EPS loss 82.25 yen loss 27.08 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001